Recombinant human VEGF165b protein is an effective anti-cancer agent in mice. - Wikidata - awgldk - TriplyDB

Recombinant human VEGF165b protein is an effective anti-cancer agent in mice.

Recombinant human VEGF165b protein is an effective anti-cancer agent in mice.

http://www.wikidata.org/entity/Q36932464

about

Vascular Endothelial Growth Factor-A165b Is Protective and Restores Endothelial Glycocalyx in Diabetic Nephropathy Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy Overexpression of VEGF165b in podocytes reduces glomerular permeability.Recombinant human VEGF165b inhibits experimental choroidal neovascularization Vascular endothelial growth factor-A165b ameliorates outer-retinal barrier and vascular dysfunction in the diabetic retina.Pro- and antiangiogenic VEGF and its receptor status for the severity of diabetic retinopathy.Knockdown of P4HA1 inhibits neovascularization via targeting glioma stem cell-endothelial cell transdifferentiation and disrupting vascular basement membrane Therapeutic potential of manipulating VEGF splice isoforms in oncology The anti-angiogenic isoforms of VEGF in health and disease.Programmed translational readthrough generates antiangiogenic VEGF-Ax VEGF-A165b is cytoprotective and antiangiogenic in the retina Molecular diversity of VEGF-A as a regulator of its biological activity.Vascular endothelial growth factor 165b expression in stromal cells and colorectal cancer Investigation of antiangiogenic tumor therapy potential of microencapsulated HEK293 VEGF165b producing cells.Do anti-angiogenic VEGF (VEGFxxxb) isoforms exist? A cautionary tale The carboxyl terminus of VEGF-A is a potential target for anti-angiogenic therapy VEGF spliced variants: possible role of anti-angiogenesis therapy.Alternative splicing of VEGFA, APP and NUMB genes in colorectal cancer Balance of pro- versus anti-angiogenic splice isoforms of vascular endothelial growth factor as a regulator of neuroblastoma growth.Ovarian VEGF(165)b expression regulates follicular development, corpus luteum function and fertility The Roles of Angiogenesis in Malignant Melanoma: Trends in Basic Science Research over the Last 100 Years.Anti-VEGF therapy in the management of retinopathy of prematurity: what we learn from representative animal models of oxygen-induced retinopathy The role of VEGF 165b in pathophysiology Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab.VEGF-A splicing: the key to anti-angiogenic therapeutics?VEGF-A165b is an endogenous neuroprotective splice isoform of vascular endothelial growth factor A in vivo and in vitro.VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo The impact of the RBM4-initiated splicing cascade on modulating the carcinogenic signature of colorectal cancer cells.Angiogenesis factors involved in the pathogenesis of colorectal cancer.Clinical imaging of tumor angiogenesis.Group V Secreted Phospholipase A2 Induces the Release of Proangiogenic and Antiangiogenic Factors by Human Neutrophils.Effects of exogenous VEGF(165)b on invasion and migration of human lung adenocarcinoma A549 cells.Sp1 inhibition-mediated upregulation of VEGF 165 b induced by rh-endostatin enhances antiangiogenic and anticancer effect of rh-endostatin in A549.VEGF₁₂₁b and VEGF₁₆₅b are weakly angiogenic isoforms of VEGF-A.Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors.Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.

P2860

Q27342809-990938FD-6D11-46B1-ADBE-C69ADAE0D923 Q30455612-B8B8A090-C9DF-42EC-8115-5ACE7C9C583A Q30497786-45F21987-E49A-4550-9FDF-5A292A613B97 Q33541827-B5CB36BF-4135-4F7A-BAA2-51B7A9DBBD31 Q33742338-A6DB5F57-271A-4079-9DCC-C5250566EC58 Q33828636-4CC2EFF7-D640-4741-B3E2-4BC2ECE2D0E4 Q33829344-AF2218ED-A0D4-489F-B08D-6767FC6D4AD6 Q33888458-885308F0-1A5B-4535-BE24-25782BC2AAA8 Q33901839-4F7B9F25-2AC7-4774-AAE9-AE582798FD46 Q33959462-0CAF4036-CACF-4259-A508-C8E207FF95F2 Q34022623-1391C05C-A4C5-4067-B7EA-B10EA688016F Q34089123-B5598E04-C0AE-4813-9EF7-9669BFFF1349 Q34101611-1EECBDCD-48E2-4335-BA20-26FB41DBE1EC Q34210916-23D18543-561A-4F7C-AF57-B211AFE52FE1 Q34261539-00C9BB81-4B22-4766-9595-93EC6418187A Q34792239-80F33C8F-6003-404D-B387-2C95C3E037BC Q35369677-842ED9D4-7329-4649-8FF6-B8E49353E258 Q35692268-2E196F18-59E6-4A58-B01C-B5CF7698A07E Q35780472-27C47D89-D065-439D-A4D1-037992A8A10B Q35885946-729AD514-95F1-430F-9A2D-73B5231381DD Q36037600-6204EDE1-A2E3-449A-BD1D-D2F15C4525DD Q36379513-57A048CB-0C9E-4F61-BFC9-3ECAEAABE1BA Q36542093-50B7A80E-C881-4127-A9C2-DD5EF0CC01C9 Q36700844-5F4C81BB-D252-4079-9AAE-D50BA490449A Q37035757-A3323B4F-8D44-4D7D-9C05-F8274D8948FD Q37149053-80EE1441-0BDC-451E-8013-C42C2A8AE6B8 Q37400534-7CBDACB7-6B2E-449E-ABCB-B091AD57A521 Q37690348-5ED865C5-FA8A-40B1-95F1-15378EC3ECA3 Q37735575-18B9670F-DBDE-4288-9394-B8C4E03A5596 Q38059503-F728035F-367F-414A-8E51-812CA741BFE5 Q38811622-8FDBFB62-1C08-4B74-85F2-02464AE25AFF Q39450742-96F13D57-DDFD-449F-BF24-59CBE582588D Q39569640-D1B40237-595B-4436-8791-934EE7BB8EC2 Q39613701-A1699AF8-5942-4F09-B2F2-80DDC6EFBB72 Q43213739-440F60D9-36D9-4FBD-B681-BEF147A3B8B8 Q52564290-060D054C-B1F7-442C-8706-89C2EC66E63D

P2860

Recombinant human VEGF165b protein is an effective anti-cancer agent in mice.

http://www.wikidata.org/entity/Q36932464

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Recombinant human VEGF165b protein is an effective anti-cancer agent in mice.

@en

type

label

Recombinant human VEGF165b protein is an effective anti-cancer agent in mice.

@en

prefLabel

Recombinant human VEGF165b protein is an effective anti-cancer agent in mice.

@en

P1433

Q36932464-E7AE5745-581C-4592-A2F5-0CD96E86E252

P1476

Q36932464-1541C7BD-DA26-4098-B169-E7915D568BDC

P2093

Q36932464-04C7F15A-FE2C-41E7-B07E-B4FC05F50891

Q36932464-3114851D-25FB-4CAC-AC2C-097906CD6E6A

Q36932464-778CAE8C-81CE-4606-BA1D-8A5D9AC02722

Q36932464-82EACB7C-9258-4A7D-BFD5-81638A777C31

Q36932464-97AC5FDE-EAFA-464F-9CDC-D8028A95BB3E

Q36932464-A6D1A22C-A450-404D-A531-5993D7A5F02E

Q36932464-B4259B3E-5E46-4232-B06C-D80844354439

Q36932464-B475E3F6-FCB1-4FA4-B600-13B40BA5D287

Q36932464-BAB60612-5F6F-44D6-A0B1-68BD52D0946F

Q36932464-F4B329F1-6C69-4A0E-BBC3-DEBD1999FCE6

P2860

Q36932464-53EF7C83-B4EA-4F8A-A179-381709F0D6AC

Q36932464-6951F4C1-E306-4A66-8B53-417292D503DC

Q36932464-75238B10-3865-4703-98C0-E31B65962F4D

Q36932464-7F8D98AF-6D49-413C-A311-619F7A18CE2B

Q36932464-834BE7F1-D1C4-4C7B-8271-59B1D32922DD

Q36932464-8BD3BF36-CEC8-4B14-AA61-38D3E48E3AAE

Q36932464-8E296BE0-DB4F-4C2A-816F-89B2F25F1761

Q36932464-A1C44124-0751-479D-98F2-D62D581A0319

Q36932464-AD1900EF-91E2-4453-8090-CDA33C98A803

Q36932464-B3E5CAF8-35DC-4C16-BCBE-211D408E4CD4

P304

Q36932464-813C2BB8-291B-4BF5-9B1A-307DBA7BE012

P31

Q36932464-7F96DB70-0577-43DD-AD53-EEF33C6640AB

P356

Q36932464-B9BBAB66-8E88-479A-878F-CC57705BC6B2

P433

Q36932464-7A992568-846D-4562-A2CC-87F306E0DBD1

P478

Q36932464-324A1C06-E2DD-40C4-859B-1F785FEC5316

P50

Q36932464-2901EDD3-7E0F-4E6D-9497-81E3453C41F9

Q36932464-6A9521AD-D751-46E8-893C-A5B9FC67BE6A

P577

Q36932464-406C1390-F187-46BC-BC1D-7BD38DBC7956

P5875

Q36932464-FEC98ED3-75A3-4847-A42E-4C1AF30C1E7F

P698

Q36932464-54444D42-4033-46DA-AD68-21EE974C7250

P932

Q36932464-220C506F-F392-4598-855C-2EE71C1835E1

P356

J.EJCA.2008.05.027

P1433

European Journal of Cancer

P1476

Recombinant human VEGF165b protein is an effective anti-cancer agent in mice

@en

P2093

Anette Magnussen

http://www.w3.org/2001/XMLSchema#string

Ciara Finucane

http://www.w3.org/2001/XMLSchema#string

David Ellison

http://www.w3.org/2001/XMLSchema#string

Edward R Wheatley

http://www.w3.org/2001/XMLSchema#string

Emma S Rennel

http://www.w3.org/2001/XMLSchema#string

Lorna Stewart

http://www.w3.org/2001/XMLSchema#string

Maryam A Hamdollah-Zadeh

http://www.w3.org/2001/XMLSchema#string

Sara P Kelly

http://www.w3.org/2001/XMLSchema#string

Stephanie Cebe-Suarez

http://www.w3.org/2001/XMLSchema#string

Stephen Mather

http://www.w3.org/2001/XMLSchema#string

P2860

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

Vascular endothelial growth factor: basic science and clinical progress.

A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2.

The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice.

VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy.

VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression.

Iodine-123-vascular endothelial growth factor-165 (123I-VEGF165). Biodistribution, safety and radiation dosimetry in patients with pancreatic carcinoma.

VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma.

Substantially attenuated hemodynamic responses to Escherichia coli-derived vascular endothelial growth factor given by intravenous infusion compared with bolus injection.

P304

1883-1894

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EJCA.2008.05.027

http://www.w3.org/2001/XMLSchema#string

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P50

Kurt Ballmer-Hofer

P577

2008-07-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51430475

http://www.w3.org/2001/XMLSchema#string

P698

18657413

http://www.w3.org/2001/XMLSchema#string

P932

2565644

http://www.w3.org/2001/XMLSchema#string